Effect of prolonged beta-carotene or DL-alpha-tocopheryl acetate supplementation on ornithine decarboxylase activity in human atrophic stomach mucosa.
The effect of beta-carotene and DL-alpha-tocopheryl acetate (alpha-TAc) on the activity of ornithine decarboxylase (ODC) in human atrophic stomach mucosa and intestinal metaplasia (IM) was studied in a double-blind intervention trial. Persons (227) with upper gastrointestinal symptoms and/or atrophic gastritis (AG) were examined. It was found that ODC activity in the biopsies of antral mucosa increased gradually from normal mucosa (7.2 +/- 1.8 units) to superficial gastritis (22.7 +/- 5.9 units) and to AG (54.2 +/- 6.9 units). Enzyme activity in cases of IM did not differ from atrophic mucosa without IM (56.1 +/- 8.0 versus 51.4 +/- 5.6 units; P > 0.05). For the intervention trial, 3 groups of 20 patients with AG were studied. Patients were supplemented daily for 1 year with beta-C (20 mg; group 1), alpha-TAc (55 mg; group 2), or placebo (group 3). No significant change in ODC activity was observed in placebo-treated subjects during 1-year follow-up. During the first 3 months, beta-C supplementation resulted in about a 50% decrease in ODC activity in atrophic mucosa. A moderate decrease in ODC activity of approximately 18% was observed after 6 months supplementation with alpha-TAc. The possible role of ODC in gastric carcinogenesis is discussed.
Bukin
Y V
YV
Department of Cancer Epidemiology and Prevention, Cancer Research Center of Russian Academy of Medical Sciences, Moscow, Russia.
Draudin-Krylenko
V A
VA
Orlov
E N
EN
Kuvshinov
Y P
YP
Poddubny
B K
BK
Vorobyeva
O V
OV
Shabanov
M A
MA
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000008:administration & dosage / Q000627:therapeutic use*; D001706:Biopsy; D002338:Carotenoids / Q000008:administration & dosage / Q000627:therapeutic use*; D016001:Confidence Intervals; D004311:Double-Blind Method; D004334:Drug Administration Schedule; D005260:Female; D005753:Gastric Mucosa / Q000187:drug effects / Q000201:enzymology* / Q000473:pathology; D005757:Gastritis, Atrophic / Q000188:drug therapy* / Q000473:pathology; D005773:Gastroscopy; D006801:Humans; D008297:Male; D008875:Middle Aged; D009955:Ornithine Decarboxylase / Q000187:drug effects* / Q000378:metabolism; D024505:Tocopherols; D016896:Treatment Outcome; D014810:Vitamin E / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D024502:alpha-Tocopherol / Q000031:analogs & derivatives*
D000975:Antioxidants; D014810:Vitamin E; D002338:Carotenoids; D009955:Ornithine Decarboxylase; D024502:alpha-Tocopherol; D024505:Tocopherols